Chondropsin-class antitumor v-atpase inhibitor compounds, compositions and methods of use thereof

A method of preventing or treating a patient for cancer, which method comprises administering to the patient an anticancer effective amount of at least one compound of the formula:

• wherein:
• R1 is H, a straight-chain or branched C1-30 saturated alkyl, a straight-chain or branched C2-30 unsaturated alkyl, or an aryl comprising 6-10 carbon atoms in the ring skeleton thereof, wherein R1 is unsubstituted or substituted with one or more substituents, which are the same or different, selected from the group consisting of a halogen, an oxo, OR1a, CO2R1a, and OC(O)R1a, wherein R1a is H, a straight-chain or branched C1-30 saturated alkyl, a straight-chain or branched C2-30 unsaturated alkyl, or an aryl comprising 6-10 carbon atoms in the ring skeleton thereof;
• R2-R8 are the same or different and each is R10, C(O)R10, SO3R10, or SO2R10, wherein R10 is H, a straight-chain or branched C1-30 saturated alkyl, a straight-chain or branched C2-30 unsaturated alkyl, or an aryl comprising 6-10 carbon atoms in the ring skeleton thereof, wherein R10 is unsubstituted or substituted with one or more substituents, which are the same or different, selected from the group consisting of a halogen, an oxo, OR10a, CO2R10a and OC(O)R10a, wherein R10a is H, a straight-chain or branched C1-30 saturated alkyl, a straight-chain or branched C2-30 unsaturated alkyl, or an aryl comprising 6-10 carbon atoms in the ring skeleton thereof;
• and
• R9 is a substituent of the formula:
• wherein the R9a substituents are the same or different and each is R11, C(O)R11, or SO2R11, wherein R11 is H, a straight-chain or branched C1-30 saturated alkyl, a straight-chain or branched C2-30 unsaturated alkyl, or an aryl comprising 6-10 carbon atoms in the ring skeleton thereof, wherein R11 is unsubstituted or substituted with one or more substituents, which are the same or different, selected from the group consisting of a halogen, an oxo, OR11a, CO2R11a and OC(O)R11a, wherein R11a is H, a straight-chain or branched C1-30 saturated alkyl, a straight-chain or branched C2-30 unsaturated alkyl, or an aryl comprising 6-10 carbon atoms in the ring skeleton thereof;
• wherein R1a, R10a and R11a are unsubstituted or substituted with one or more substituents selected from the group consisting of a halogen, an oxo, and a hydroxyl;
• or a pharmaceutically acceptable salt thereof,
• whereupon the patient is treated for cancer.

A method of inhibiting vacuolar-type (H+)-ATPase in a patient in need thereof, the method comprising administering to the patient a vacuolar-type (H+)-ATPase-inhibiting effective amount of at least one compound of the formula:

• wherein:
• R1 is H, a straight-chain or branched C1-30 saturated alkyl, a straight-chain or branched C2-30 unsaturated alkyl, or an aryl comprising 6-10 carbon atoms in the ring skeleton thereof, wherein R1 is unsubstituted or substituted with one or more substituents, which are the same or different, selected from the group consisting of a halogen, an oxo, OR1a, CO2R1a, and OC(O)R1a, wherein R1a is H, a straight-chain or branched C1-30 saturated alkyl, a straight-chain or branched C2-30 unsaturated alkyl, or an aryl comprising 6-10 carbon atoms in the ring skeleton thereof;
• R2-R8 are the same or different and each is R10, C(O)R10, SO3R10, or SO2R10, wherein R10 is G, a straight-chain or branched C1-30 saturated alkyl, a straight-chain or branched C2-30 unsaturated alkyl, or an aryl comprising 6-10 carbon atoms in the ring skeleton thereof, wherein R10 is unsubstituted or substituted with one or more substituents, which are the same or different, selected from the group consisting of a halogen, an oxo, OR10a, CO2R10a and OC(O)R11a, wherein R10a is H, a straight-chain or branched C1-30 saturated alkyl, a straight-chain or branched C2-30 unsaturated alkyl, or an aryl comprising 6-10 carbon atoms in the ring skeleton thereof;
• and
• R9 is a substituent of the formula:
• wherein the R9a substituents are the same or different and each is R11, C(O)R11, or SO2R11, wherein R11 is H, a straight-chain or branched C1-30 saturated alkyl, a straight-chain or branched C2-30 unsaturated alkyl, or an aryl comprising 6-10 carbon atoms in the ring skeleton thereof, wherein R11 is unsubstituted or substituted with one or more substituents, which are the same or different, selected from the group consisting of a halogen, an oxo, OR11a, CO2R11a and OC(O)R11a, wherein R11a is H, a straight-chain or branched C1-30 saturated alkyl, a straight-chain or branched C2-30 unsaturated alkyl, or an aryl comprising 6-10 carbon atoms in the ring skeleton thereof;
• wherein R1a, R10a and R11a are unsubstituted or substituted with one or more substituents selected from the group consisting of a halogen, an oxo, and a hydroxyl;
• or a pharmaceutically acceptable salt thereof,
• whereupon vacuolar-type (H+)-ATPase in the patient is inhibited.